

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Acton, Susan L.
Application No.: TBA Group No.: TBA
Filed: Herewith Examiner: TBA
For: NOVEL PROTEIN KINASE MOLECULES AND USES THEREFOR

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) (4 pages)
- 3.. ☒ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a) **37 C.F.R. SECTION 1.10***
- ☐ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Addressee"
Mailing Label No. EV439625520US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Date: February 25, 2004

Sean Hunziker
(type or print name of person certifying)

Practitioner's Docket No. **MPI98-052P1RDV10DV1M**

Preliminary Statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial No.: 09/ 757,982 , filed on January 10, 2001.

The following references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, in the event additional copies are necessary, the undersigned will submit such copies upon request.

February 25, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat
Tracy M. Sioussat
Registration No. 50,609
40 Landsdowne Street
Cambridge, MA 02139
Telephone – (617) 374-7679
Facsimile – (617) 551-8820

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	TBA
				Filing Date	Herewith
				First Named Inventor	Acton, Susan L.
				Group Art Unit	TBA
				Examiner Name	TBA
Sheet	1	of	1	Attorney Docket Number	MPI98-052P1RDV10DV1M

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	6,180,358		Acton	01-2001	
	A2	6,258,582		Acton	07-2001	
	A3	6,146,832		Acton	11-2000	
	A4	6,121,030		Acton	09-2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	WO	98/11234	03/98				

Examiner Signature	Date Considered
-------------------------------	----------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	TBA
		Filing Date	Herewith
		First Named Inventor	Acton, Susan L.
		Group Art Unit	TBA
		Examiner Name	TBA
		Attorney Docket Number	MPI98-052P1RDV10DV1M
Sheet	1	of	3

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C1	GenBank Accession Number AA746653 for Homo Sapiens cDNA clone 1257327, January 22, 1990	
	C2	GenBank Accession Number AA937590 for Homo Sapiens cDNA clone 1425841, August 24, 1998	
	C3	GenBank Accession Number AA503192 for Homo Sapiens cDNA clone 956612, August 20, 1997	
	C4	GenBank Accession Number B38320 for Homo Sapiens genomic clone Plate=CT 830 Col=16 Row=0, October 17, 1997	
	C5	GenBank Accession Number AL023513 for Human DNA sequence from clone 268D13, September 23, 1998	
	C6	GenBank Accession Number G21973 for Human STS WI-15835, May 31, 1996	
	C8	GenBank Accession Number AA399022 for Soares testis-NHT Homo Sapiens cDNA clone 729929, May 16, 1997	
	C9	GenBank Accession Number AA516800 for Barstead mouse myotubes MPLRB5 Mus musculus cDNA clone 902193, July 14, 1997	
	C10	GenBank Accession Number Q09298 for HYPOTHETICAL 141.2 KD PROTEIN EEED8.9, July 15, 1998	
	C11	GenBank Accession Number AA307961 for Colon carcinoma (HCC) cell line II Homo Sapiens cDNA, April 18, 1997	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin-top: 10px;"><i>(use as many sheets as necessary)</i></p>				<h3 style="text-align: center; margin: 0;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;">TBA</td> </tr> <tr> <td>Filing Date</td> <td>Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Acton, Susan L.</td> </tr> <tr> <td>Group Art Unit</td> <td>TBA</td> </tr> <tr> <td>Examiner Name</td> <td>TBA</td> </tr> <tr> <td>Attorney Docket Number</td> <td>MPI98-052P1RDV10DV1M</td> </tr> </table>		Application Number	TBA	Filing Date	Herewith	First Named Inventor	Acton, Susan L.	Group Art Unit	TBA	Examiner Name	TBA	Attorney Docket Number	MPI98-052P1RDV10DV1M
Application Number	TBA																
Filing Date	Herewith																
First Named Inventor	Acton, Susan L.																
Group Art Unit	TBA																
Examiner Name	TBA																
Attorney Docket Number	MPI98-052P1RDV10DV1M																
Sheet	2	of	3														

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²	
	C12	GenBank Accession Number AA307684 for Colon carcinoma (HCC) cell line II Homo Sapiens cDNA, April 18, 1997		
	C13	GenBank Accession Number AA310905 Jurkat T-cells V Homo Sapiens cDNA , April 9, 1997		
	C14	Adams, M. D. et al., "Initial Assessment of Human Gene Diversity and Expression Patterns Based Upon 83 Million Nucleotides of cDNA Sequence," Nature 377:3-174 (1995)		
	C15	Jurka, J. et al., "Reconstruction and Analysis of Human Alu Genes," J. Mol. Evol. 32(2):105-121 (1991)		
	C16	Claverie, J-M. et al., "Alu Alert," Nature 371 :752 (1994)		
	C17	Nagase, T. et al., "Prediction of the coding Sequences of Unidentified Human Genes. IX. The Complete Sequence of 100 new cDNA Clones From the Brain Which Can Code for Large Proteins in Vitro," DNA Res. 5:31-39 (1998)		
	C18	Schultz, S. J. et al., "Identification of 21 Novel Human Protein Kinases, Including 3 Members of a Family Related to the Cell Cycle Regulator nimA of Aspergillus Nidulans," Cell Growth Differ. 4(10):821-830 (1993)		
	C19	Schultz, S. J. et al., "Cell Cycle-Dependent Expression of Nek2, a Novel Human Protein Kinase Related to the NIMA Mitotic Regulator of Aspergillus Nidulans," Cell Growth Differ. 5(6):625-635 (1994)		
	C20	Katoh, M. et al., "Cloning and Characterization of MST, a Novel (Putative) Serine/Threonine Kinase with SH3 Domain," Oncogene 10(7):1447-1451 (1995)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;"><i>(use as many sheets as necessary)</i></p>		<h3 style="text-align: center;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>TBA</td> </tr> <tr> <td>Filing Date</td> <td>Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Acton, Susan L.</td> </tr> <tr> <td>Group Art Unit</td> <td>TBA</td> </tr> <tr> <td>Examiner Name</td> <td>TBA</td> </tr> <tr> <td>Attorney Docket Number</td> <td>MPI98-052P1RDV10DV1M</td> </tr> </table>		Application Number	TBA	Filing Date	Herewith	First Named Inventor	Acton, Susan L.	Group Art Unit	TBA	Examiner Name	TBA	Attorney Docket Number	MPI98-052P1RDV10DV1M
Application Number	TBA														
Filing Date	Herewith														
First Named Inventor	Acton, Susan L.														
Group Art Unit	TBA														
Examiner Name	TBA														
Attorney Docket Number	MPI98-052P1RDV10DV1M														
Sheet	3	of	3												

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C21	Kawai T. et al., "Zip-Kinase, A Novel Serine/threonine Kinase which Mediates Apoptosis," Mol. Cell Biol. 18:1642-1651 (1998)	
	C22	Dorow, D. S. et al., "Identification of a New Family of Human Epithelial Protein Kinases Containing Two Leucine/isoleucine-Zipper Domains," Eur. J. Biochem. 213(2):701-710 (1993)	
	C23	Deiss, L. P. et al., "Identification of a Novel Serine/Threonine Kinase and a Novel 15-kd protein as Potential Mediators of the Gamma Interferon-Induced Cell Death," Genes Dev. 9(1):15-30 (1995)	
	C24	Su, U. C. et al., "NIK is a New ste20-Related Kinase That Binds NCK and MEKK1 and activates the SAPK/JNK cascade via a Conserved Regulatory Domain," The EMBO Journal 16(6):1279-1290 (1997)	
	C25	Wilson, R. et al., "2.2 Mb of Contiguous Nucleotide Sequence from Chromosome III of C. Elegans," Nature 368(6466):32-38 (1994)	
	C26	Ngo, J. T. et al., "Computational complexity, protein Structure prediction, and the Levinthal Paradox in the Protein Folding Problem," Birkhauser Chapter 14:435-508 (1994)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.